The novel selective pan-TRK inhibitor ONO-7579 exhibits antitumor efficacy against human gallbladder cancer in vitro

Makoto Kawamoto, Keigo Ozono, Yasuhiro Oyama, Akio Yamasaki, Yoshinao Oda, Hideya Ohnishi

研究成果: ジャーナルへの寄稿記事

1 引用 (Scopus)

抄録

We previously reported that brain-derived neurotrophic factor (BDNF)/neurotrophic receptor tyrosine kinase 2 (NTRK2/TRKB) signaling contributes to induction of malignant phenotype of gallbladder cancer (GBC). Recently, pan-TRK inhibitors have been evaluated and their dramatic clinical activity is being shown for a variety of cancer types harboring an NTRK rearrangement in phase I trials. ONO-7579 is an oral pan-TRK inhibitor currently under investigation in phase I/II clinical trial for TRK-rearranged solid tumors. In this study, we evaluated the anticancer effect of ONO-7579 using GBC cells with or without KRAS mutant, NOZ, TYGBK-1. Our study showed that ONO-7579 had a suppressive effect on GBC proliferation in TYGBK-1, and on invasive potential and vascular endothelial growth factor expression in TYGBK-1 and NOZ. Our data indicated that ONO-7579 could be a promising treatment option for patients with GBC.

元の言語英語
ページ(範囲)1979-1986
ページ数8
ジャーナルAnticancer research
38
発行部数4
DOI
出版物ステータス出版済み - 4 1 2018

Fingerprint

Gallbladder Neoplasms
TYK2 Kinase
trkB Receptor
Phase II Clinical Trials
Clinical Trials, Phase I
Vascular Endothelial Growth Factor A
Neoplasms
Phenotype
In Vitro Techniques

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

The novel selective pan-TRK inhibitor ONO-7579 exhibits antitumor efficacy against human gallbladder cancer in vitro. / Kawamoto, Makoto; Ozono, Keigo; Oyama, Yasuhiro; Yamasaki, Akio; Oda, Yoshinao; Ohnishi, Hideya.

:: Anticancer research, 巻 38, 番号 4, 01.04.2018, p. 1979-1986.

研究成果: ジャーナルへの寄稿記事

Kawamoto, Makoto ; Ozono, Keigo ; Oyama, Yasuhiro ; Yamasaki, Akio ; Oda, Yoshinao ; Ohnishi, Hideya. / The novel selective pan-TRK inhibitor ONO-7579 exhibits antitumor efficacy against human gallbladder cancer in vitro. :: Anticancer research. 2018 ; 巻 38, 番号 4. pp. 1979-1986.
@article{92675e475f96429cb3266404c6fb1603,
title = "The novel selective pan-TRK inhibitor ONO-7579 exhibits antitumor efficacy against human gallbladder cancer in vitro",
abstract = "We previously reported that brain-derived neurotrophic factor (BDNF)/neurotrophic receptor tyrosine kinase 2 (NTRK2/TRKB) signaling contributes to induction of malignant phenotype of gallbladder cancer (GBC). Recently, pan-TRK inhibitors have been evaluated and their dramatic clinical activity is being shown for a variety of cancer types harboring an NTRK rearrangement in phase I trials. ONO-7579 is an oral pan-TRK inhibitor currently under investigation in phase I/II clinical trial for TRK-rearranged solid tumors. In this study, we evaluated the anticancer effect of ONO-7579 using GBC cells with or without KRAS mutant, NOZ, TYGBK-1. Our study showed that ONO-7579 had a suppressive effect on GBC proliferation in TYGBK-1, and on invasive potential and vascular endothelial growth factor expression in TYGBK-1 and NOZ. Our data indicated that ONO-7579 could be a promising treatment option for patients with GBC.",
author = "Makoto Kawamoto and Keigo Ozono and Yasuhiro Oyama and Akio Yamasaki and Yoshinao Oda and Hideya Ohnishi",
year = "2018",
month = "4",
day = "1",
doi = "10.21873/anticanres.12435",
language = "English",
volume = "38",
pages = "1979--1986",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4",

}

TY - JOUR

T1 - The novel selective pan-TRK inhibitor ONO-7579 exhibits antitumor efficacy against human gallbladder cancer in vitro

AU - Kawamoto, Makoto

AU - Ozono, Keigo

AU - Oyama, Yasuhiro

AU - Yamasaki, Akio

AU - Oda, Yoshinao

AU - Ohnishi, Hideya

PY - 2018/4/1

Y1 - 2018/4/1

N2 - We previously reported that brain-derived neurotrophic factor (BDNF)/neurotrophic receptor tyrosine kinase 2 (NTRK2/TRKB) signaling contributes to induction of malignant phenotype of gallbladder cancer (GBC). Recently, pan-TRK inhibitors have been evaluated and their dramatic clinical activity is being shown for a variety of cancer types harboring an NTRK rearrangement in phase I trials. ONO-7579 is an oral pan-TRK inhibitor currently under investigation in phase I/II clinical trial for TRK-rearranged solid tumors. In this study, we evaluated the anticancer effect of ONO-7579 using GBC cells with or without KRAS mutant, NOZ, TYGBK-1. Our study showed that ONO-7579 had a suppressive effect on GBC proliferation in TYGBK-1, and on invasive potential and vascular endothelial growth factor expression in TYGBK-1 and NOZ. Our data indicated that ONO-7579 could be a promising treatment option for patients with GBC.

AB - We previously reported that brain-derived neurotrophic factor (BDNF)/neurotrophic receptor tyrosine kinase 2 (NTRK2/TRKB) signaling contributes to induction of malignant phenotype of gallbladder cancer (GBC). Recently, pan-TRK inhibitors have been evaluated and their dramatic clinical activity is being shown for a variety of cancer types harboring an NTRK rearrangement in phase I trials. ONO-7579 is an oral pan-TRK inhibitor currently under investigation in phase I/II clinical trial for TRK-rearranged solid tumors. In this study, we evaluated the anticancer effect of ONO-7579 using GBC cells with or without KRAS mutant, NOZ, TYGBK-1. Our study showed that ONO-7579 had a suppressive effect on GBC proliferation in TYGBK-1, and on invasive potential and vascular endothelial growth factor expression in TYGBK-1 and NOZ. Our data indicated that ONO-7579 could be a promising treatment option for patients with GBC.

UR - http://www.scopus.com/inward/record.url?scp=85045221319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045221319&partnerID=8YFLogxK

U2 - 10.21873/anticanres.12435

DO - 10.21873/anticanres.12435

M3 - Article

VL - 38

SP - 1979

EP - 1986

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4

ER -